HMAs and HMAs/venetoclax combinations show some efficacy in TP53-mutated high-risk MDS and AML-MCR [153,163], but the incidence of relapse and long-term overall survival remains disappointing [164]. Here, TP53 is linked to myelodysplastic syndrome.